Clinical trial NCT00843037: Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma
Official title: A Investigator Initiated Phase II Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Paraganglioma
Pheochromocytoma
Keywords: PARAGANGLIOMA
PHEOCHROMOCYTOMA
SUNITINIB
PHASE II
Metastatic or locally advanced malignant paraganglioma
Metastatic or locally advanced malignant pheochromocytoma
Lead sponsor: University Health Network, Toronto
Sponsor class: OTHER
Collaborators: name: Pfizer
First posted: 2009-02-13
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is an open-label phase II study of an investigational drug, sunitinib malate in patients with advanced malignant paraganglioma or phaeochromocytoma cancer. Paragangliomas (PGs) are tumours that arise from the para-sympathetic system in the head and neck and sympathetic system in the thorax and abdomen. Paragangliomas that secrete hormones (catecholamines) from the adrenal glands are called pheochromocytomas (PCs). In this study, patients whose disease has advanced or spread despite prior standard therapy, will receive sunitinib for 4-weeks followed by a 2-week rest period, for up to 12 months, in the absence of disease progression. Sunitinib is an investigational drug, which has been shown to shrink tumours in several tumour models. The study will evaluate the efficacy as well as the toxicity profile of sunitinib when used as an alternative treatment for patients with PG/PC tumours.

Detailed description: This study will be a single arm, open-label, phase II trial of sunitinib in patients with metastatic or locally advanced malignant paraganglioma or phaeochromocytoma. Oral sunitinib (50 mg) will be administered to all patients daily for the first four weeks of a six week study cycle, followed by a 2-week rest. Patients will be assessed for response to study treatment using MRI/CT scans as well as bio-chemical tests, and will receive the study treatment for up to 12 months or until disease progression.

Primary study outcomes include:

To assess the efficacy (response rate) of sunitinib given orally daily for 4 out of every 6 weeks in patients with advanced or metastatic paraganglioma/ pheochromocytoma.

To assess the toxicity of sunitinib in patients with advanced or metastatic paraganglioma/ pheochromocytoma.

To document effects of sunitinib on markers of biochemical activity of advanced or metastatic paraganglioma/ pheochromocytoma.

Eligibility criteria: Inclusion Criteria:

* Histologically or cytologically confirmed diagnosis of malignant paraganglioma or pheochromocytoma and either evidence of metastases or unresectability.
* Evidence of recent disease progression (radiological, biochemical, symptomatic).
* Measurable disease defined as that which can be measured in at least one dimension with a minimum size of 10 mm by CT scan.
* ECOG 0-2.
* Life expectancy of greater than 24 weeks.
* Age \> 18 years.
* Patients must have normal organ and marrow function.
* Patients must have PT/INR/PTT within 1.2 X the upper limit
* Patients may have had prior radiation therapy. A minimum of 28 days must have elapsed between the end of radiotherapy and registration onto the study.
* Previous Surgery: Previous major surgery is permitted provided that it has been at least 28 days prior to patient registration
* Laboratory Requirements Parameter Limit granulocytes (AGC) \> 1.5 x 109/L platelets \> 100 x 109/L bilirubin \< 1.5XULN AST and ALT \< 2.5 x ULN Amylase \<1.5XULN Lipase \<1.5XULN Calcium \< 3 mmol/L creatinine \< 2.0XULN

Exclusion Criteria:

* History of other malignancies.
* Patients with known brain metastases.
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to sunitinib.
* Patients receiving concurrent treatment with other anti-cancer therapy given for paraganglioma or pheochromocytoma or other therapy or other investigational anticancer agents.
* Patients who have received prior treatment with any other antiangiogenic agent or multi-targeted tyrosine kinase inhibitors are ineligible.
* Patients with any of the following cardiovascular findings are to be excluded:
* QTc prolongation or other significant ECG abnormalities.
* Current or history of Class III or IV heart failure as defined by the NYHA functional classification system
* Patients with prior anthracycline exposure, previous central thoracic radiation that included heart in radiation port, or a history of NYHA Class II cardiac function.
* Poorly controlled hypertension
* Myocardial infarction, cardiac arrhythmia, stable/unstable angina, symptomatic congestive heart failure, or coronary/peripheral artery bypass graft or stenting within 12 months prior to study entry
* History of venous thrombosis or pulmonary embolism in the past 3 months
* History of cerebrovascular accident (CVA) or transient ischemic attack within 12 months prior to study entry
* Patients who require use of therapeutic doses of coumarin-derivative anticoagulants such as warfarin
* Patients with bowel obstruction or any condition that impairs their ability to swallow and retain sunitinib tablets.
* Use of agents with proarrhythmic potential is not permitted during the study.
* Must be able to stop prohibited selected CYP3A4 inhibitors/inducers prior to starting sunitinib
* Patients with pre-existing hypothyroidism prior to enrolment are ineligible unless they are euthyroid on medication.
* Pregnant or lactating women, positive pregnancy test, women of childbearing potential who do not agree to use adequate contraception prior to study entry and for the duration of study participation.
* Known HIV-positive patients on combination antiretroviral therapy
* Greater than +1 proteinuria on urinary dipstick if also \>1g urinary protein/24hrs

Primary outcomes:
measure: Clinical Benefit Rate (CBR) Which is Defined as Either a Partial Response (PR) Complete Response (CR) or Stable Disease (SD) for ≥ 12 Weeks Measured Using Response Evaluation Criteria in Solid Tumors (RECIST) Criteria.
timeFrame: Every 12 weeks (2 cycles) up to disease progression or study discontinuation (an average of 13.5 6-week cycles or about 1.5 years).
Secondary outcomes:
measure: Biochemical Response (BCR) of > 20% Drop in 24-hour Urinary Metanephrines, Catecholamines or Serum Chromogranin A, Sustained for > 12-week Period
timeFrame: Within 7 days of study registration and every 12 weeks (2 cycles) up to treatment discontinuation (an average of 13.5 6-week cycles or about 1.5 years).
measure: Overall Survival
timeFrame: From time of enrollment until loss to follow-up or death (approximately 125 months for longest patient on treatment).
measure: Time to Progression
timeFrame: Every 12 weeks (2 cycles) up to disease progression or study discontinuation (an average of 13.5 6-week cycles or about 1.5 years).
measure: Overall Response Rate (PR) + (CR)
timeFrame: Every 12 weeks (2 cycles) up to disease progression or study discontinuation (an average of 13.5 6-week cycles or about 1.5 years).
Other outcomes:
Locations:
city: Calgary
country: Canada
facility: Tom Baker Cancer Centre
state: Alberta
city: Toronto
country: Canada
facility: University Health Network, Princess Margaret Cancer Centre
state: Ontario
city: Montreal
country: Canada
facility: Hôpital Notre-Dame du CHUM
state: Quebec
city: Groningen
country: Netherlands
facility: University Medical Centre Groningen
Study officials:
affiliation: The Princess Margaret Cancer Foundation
name: Jennifer Knox, MD, FRCPC
role: PRINCIPAL_INVESTIGATOR
References: